EUVIMEDEUVIMED entdecken
BeobachtungsstudieMultizentrische Studie

MiniMed 780G Advanced Hybrid Closed-Loop System Outcomes According to Pubertal Status: Awesome Study Group Real-Life Experience

Marianna Rachmiel iD, Yael Lebenthal iD, Kineret Mazor-Aronovitch iD, Avivit Brener iD, Noah Levek iD, Talia Jacobi-Polishook, Tal Ben Ari, Shirli Abiri, Zohar Landau iD, Orit Pinhas-Hamiel iD

Diabetes Technology & Therapeutics · 2023-09 · 25 (9) · 643-651

DOI: 10.1089/dia.2023.0081 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Diabetes Technology & Therapeutics, online erschienen am 23.08.2023. Verfasst von Marianna Rachmiel und 9 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Endocrinology Unit, Shamir (Assaf Harofeh) Medical Center, Beer Yaakov, Israel. Hauptthemen laut MEDLINE: Blood Glucose, Diabetes Mellitus, Type 1. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims: Achieving good glycemic control is a major challenge for adolescents with type 1 diabetes (TID). The introduction of the MiniMed 780G system, an advanced hybrid closed-loop (AHCL) that enables an automatic correction of insulin, gave hope for improved glycemic outcomes in adolescents. We assessed specific characteristics associated with glycemic measures in youth with T1D switching to Minimed 780G.

Methods

This retrospective observational real-life multicenter study from the AWeSoMe Group assessed continuous glucose monitoring (CGM) metrics of 22 patients (59% females, median age 13.9 interquartile range [IQR 11,18] years), from a high socioeconomic background. CGM metrics were recorded for 2-week periods before AHCL, after 1, 3, 6 months, and at the end of follow-up (median 10.9 [IQR 5.4, 17.4] months). Delta-variables (Δ) were calculated as the difference between the end of follow-up and baseline.

Results

Time in range (TIR) 70–180mg/dL increased from 65% [52, 72] to 75% [63, 80], P = 0.008, from baseline to end of follow-up. Time above range >180mg/dL decreased from 28% [20, 46] to 22% [14, 35], P = 0.047. Advanced pubertal stage was correlated with less improvement in ΔTAR >180mg/dL , r = 0.47, P = 0.05, and less CGM usage r = −0.57, P = 0.05. A longer disease duration was associated with less improvement in ΔTAR 180–250mg/dL , r = 0.48, P = 0.05. Lower pump site change frequency was associated with higher glucose management indicator, r = 0.5, P = 0.03, and lower TIR 70–180mg/dL r = −0.52, P = 0.08.

Conclusion

The use of AHCL enabled improvements in TIR 70–180mg/dL in youth with T1D. More advanced pubertal stages, longer disease duration, and less compliance were associated with less improvement, stressing the need for continuous support, and re-education in this age group.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Blood GlucoseDiabetes Mellitus, Type 1AdolescentFemaleHumansMaleBlood Glucose Self-MonitoringRetrospective StudiesInsulin, Regular, HumanInsulinHypoglycemic AgentsInsulin Infusion Systems

Stichwörter der Autor:innen

AdolescentsGlycemic controlPubertyTime in range

Substanzen

Blood GlucoseInsulin, Regular, HumanInsulinHypoglycemic Agents

Autor:innen und Institutionen

  • Pediatric Endocrinology Unit, Shamir (Assaf Harofeh) Medical Center, Beer Yaakov, Israel.
  • Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Pediatric Endocrinology and Diabetes Unit, Dana-Dwek Children's Hospital, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
  • National Juvenile Diabetes Center, Maccabi Health Care Services, Ra'anana, Israel.
  • Pediatric Endocrine and Diabetes Unit, Edmond and Lily Safra Children's Hospital, Chaim Sheba Medical Center, Ramat-Gan, Israel.
  • Pediatric Endocrine and Diabetes Unit, E. Wolfson Medical Center, Holon, Israel.

ORCID-Profile: Marianna Rachmiel, Yael Lebenthal, Kineret Mazor-Aronovitch, Avivit Brener, Noah Levek, Zohar Landau, Orit Pinhas-Hamiel

Zitieren

APA

Rachmiel, M., Lebenthal, Y., Mazor-Aronovitch, K., Brener, A., Levek, N., Jacobi-Polishook, T., Ben Ari, T., Abiri, S., Landau, Z., & Pinhas-Hamiel, O. (2023). MiniMed 780G Advanced Hybrid Closed-Loop System Outcomes According to Pubertal Status: Awesome Study Group Real-Life Experience. Diabetes Technology & Therapeutics, 25(9), 643-651. https://doi.org/10.1089/dia.2023.0081

Vancouver

Rachmiel M, Lebenthal Y, Mazor-Aronovitch K, Brener A, Levek N, Jacobi-Polishook T, et al. MiniMed 780G Advanced Hybrid Closed-Loop System Outcomes According to Pubertal Status: Awesome Study Group Real-Life Experience. Diabetes Technology & Therapeutics. 2023;25(9):643-651. doi:10.1089/dia.2023.0081

BibTeX
@article{Rachmiel2023,
  author = {Rachmiel, Marianna and Lebenthal, Yael and Mazor-Aronovitch, Kineret and Brener, Avivit and Levek, Noah and Jacobi-Polishook, Talia and Ben Ari, Tal and Abiri, Shirli and Landau, Zohar and Pinhas-Hamiel, Orit},
  title = {MiniMed 780G Advanced Hybrid Closed-Loop System Outcomes According to Pubertal Status: Awesome Study Group Real-Life Experience},
  journal = {Diabetes Technology & Therapeutics},
  year = {2023},
  volume = {25},
  number = {9},
  pages = {643--651},
  doi = {10.1089/dia.2023.0081}
}
Kostenlos starten →